Clinical Research Directory

Asymptomatic Cohort Inclusion Criteria: 1. Clinically and/or pathologically diagnosed with any one of the 13 invasive cancers including lung cancer, gastric cancer, etc., or diagnosed with high-risk precancerous lesions / carcinoma in situ corresponding to these 13 cancers. 2. 50-74 years old. 3. Self-reported absence of prespecified symptoms related to the corresponding cancer prior to diagnosis. 4. No prior or undergoing any systemic or local antitumor therapy, including but not limited to surgical resection, radiochemotherapy, endocrinotherapy, targeted therapy, immunotherapy, interventional therapy, etc 5. Able to provide a written informed consent and willing to comply with all part of the protocol procedures Exclusion Criteria: 1. Female subjects with self-reported pregnancy. 2. Severe infection within 14 days before screening. 3. Recipients of blood transfusion within 7 days prior to screen 4. With active autoimmune disease, such as rheumatoid arthritis, ankylosing spondylitis, systemic lupus erythematosus, psoriasis, etc. 5. Other conditions judged by the investigator to render the subject ineligible for participation in this study. TOO Model Optimization Cohort: Inclusion Criteria: 1. Clinically and/or pathologically diagnosed with any of the following diseases: urothelial carcinoma of the bladder, advanced colorectal adenomas, high-grade gastric intraepithelial neoplasia, or high-grade esophageal intraepithelial neoplasia 2. 50-74 years old. 3. No prior or undergoing any systemic or local antitumor therapy, including but not limited to surgical resection, radiochemotherapy, endocrinotherapy, targeted therapy, immunotherapy, interventional therapy, etc 4. Able to provide a written informed consent and willing to comply with all part of the protocol procedures. Exclusion Criteria: 1. Female subjects with self-reported pregnancy. 2. Severe infection within 14 days before screening. 3. Recipients of blood transfusion within 7 days prior to screen 4. With active autoimmune disease, such as rheumatoid arthritis, ankylosing spondylitis, systemic lupus erythematosus, psoriasis, etc. 5. Other conditions judged by the investigator to render the subject ineligible for participation in this study.